Announcing a change of leadership at the US Philadelphia office
Research Partnership’s Philadelphia office is announcing a change of leadership from the start of 2020. President Harriet Kozak will be stepping down in order to take retirement at the end of 2019, and will be replaced by Sabera Hyderally, current Director of MedTech, North America, who will take over as the Head of the Philadelphia office from 2nd January 2020.
Mandira Kar joins as Research Director
We are delighted to announce that Mandira Kar has joined Research Partnership as a Qualitative Research Director. Mandira is an expert in ethnography with over 15 years’ experience in market research, and joins us from Ipsos Healthcare Ethnography. She has previously worked in a wide range of research industries including consumer and digital and has experience in many global markets, especially emerging markets, having lived and worked for a number of years in India.
New appointments in our UK headquarters
Research Partnership is delighted to announce new appointments in our UK headquarters. Aiyaz Mohammed joins as Associate Director in Therapy Watch, Tilly Lowkis joins as Business Development Manager and Apriya Rathour joins as Business Development Executive. We also welcomed an intake of 4 new Graduates to the UK office.
Research Partnership welcomes Jeanne Penn
We are delighted to announce that Jeanne Penn has joined the Singapore office as a Senior Research Executive.
Jeanne previously worked at Cello Health Insight in New York City on the qualitative team, where she was involved in all parts of the research process, from writing proposals to delivering reports. She’s worked in various therapy areas, and has a particular interest in rare diseases and mental health. In a prior role, she co-led the first Diversity & Inclusion initiative and was awarded the Young Professionals Grant to attend the Qualitative Research Consultants Association (QRCA) conference. Jeanne graduated from Hamilton College, and interned at Hall & Partners where she was first introduced to healthcare market research.
Therapy Watch launches a new Migraine tracker
This multi country study will report on patients with Migraine prophylaxis. The new class of CGRP inhibitors (Aimovig, Ajovy, and Emgality) look set to shake up the migraine prophylaxis market, a market which has seen little innovation in the last decade and in which there still remains considerable unmet patient need.